Literature DB >> 10409128

Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas.

S Yibchok-Anun1, H Cheng, P A Heine, W H Hsu.   

Abstract

We characterized the receptors that mediate arginine vasopressin (AVP)- and oxytocin (OT)-induced glucagon release by use of a number of antagonists in the perfused rat pancreas and the fluorescence imaging of the receptors. AVP and OT (3 pM-3 nM) increased glucagon release in a concentration-dependent manner. The antagonist with potent V(1b) receptor-blocking activity, CL-4-84 (10 nM), abolished AVP (30 pM)-induced glucagon release but did not alter OT (30 pM)-induced glucagon release. d(CH(2))(5)[Tyr(Me)(2)]AVP (10 nM), a V(1a) receptor antagonist, and L-366,948 (10 nM), a highly specific OT-receptor antagonist, failed to inhibit AVP-induced glucagon release. In contrast, L-366,948 (10 nM) abolished OT (30 pM)-induced glucagon release but did not change the effect of AVP. Fluorescent microscopy of rat pancreatic sections showed that fluorescence-labeled AVP and OT bound to their receptors in the islets of Langerhans and that the bindings were inhibited by 1 microM of Cl-4-84 and L-366,948, respectively. Because AVP and OT at physiological concentrations (3-30 pM) increased glucagon release, we conclude that AVP and OT increase glucagon release under the physiological condition through the activation of V(1b) and OT receptors, respectively.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409128     DOI: 10.1152/ajpendo.1999.277.1.E56

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Mechanisms of AVP-induced glucagon release in clonal alpha-cells in-R1-G9: involvement of Ca(2+)-dependent and -independent pathways.

Authors:  S Yibchok-Anun; H Cheng; T H Chen; W H Hsu
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

Review 3.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Arginine vasopressin inhibits adipogenesis in human adipose-derived stem cells.

Authors:  Tran D N Tran; Shaomian Yao; Walter H Hsu; Jeffrey M Gimble; Bruce A Bunnell; Henrique Cheng
Journal:  Mol Cell Endocrinol       Date:  2015-02-16       Impact factor: 4.102

5.  Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats.

Authors:  Sun Shin Yi; In Koo Hwang; Yo Na Kim; Il Yong Kim; Son-Il Pak; In Se Lee; Je Kyung Seong; Yeo Sung Yoon
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

6.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 7.  The vasopressin Avpr1b receptor: molecular and pharmacological studies.

Authors:  Ja Roper; A-M O'Carroll; Ws Young; Sj Lolait
Journal:  Stress       Date:  2010-09-09       Impact factor: 3.493

8.  Low water intake and risk for new-onset hyperglycemia.

Authors:  Ronan Roussel; Léopold Fezeu; Nadine Bouby; Beverley Balkau; Olivier Lantieri; François Alhenc-Gelas; Michel Marre; Lise Bankir
Journal:  Diabetes Care       Date:  2011-10-12       Impact factor: 19.112

9.  A complex selection signature at the human AVPR1B gene.

Authors:  Rachele Cagliani; Matteo Fumagalli; Uberto Pozzoli; Stefania Riva; Matteo Cereda; Giacomo P Comi; Linda Pattini; Nereo Bresolin; Manuela Sironi
Journal:  BMC Evol Biol       Date:  2009-06-01       Impact factor: 3.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.